Natera reports record Q2 2026 results: 283,000 Signatera tests (+56% YoY), total revenue $753M (+38% YoY), guidance raised to $2.85-2.91B

Natera/Signatera

Natera reported strong Q2 2026 financial results, with Signatera oncology tests reaching 283,000, representing 56% year-over-year growth. Total company revenue reached $753M, up 38% YoY, with full-year 2026 guidance raised, demonstrating accelerating market adoption of MRD testing.

• Signatera test volume grew 56% year-over-year to 283,000 tests in Q2 2026.
• Average selling price (ASP) increased to approximately $1,275 per test.
• Total company record: 1.04 million tests processed in Q2 2026.
• Full-year 2026 revenue guidance raised to $2.85-2.91B, implying approximately 31% annual growth.